Ivonescimab received IND clearance in China in June 2019. A database entry on the drug notes “IND approval granted in June 2019,” and a separate source shows its clinical phase starting on June 1, 2019.

If you want the exact CDE filing date or the first clinical-trial registration tied to that IND, I can help narrow it down.